病例报告:在非小细胞肺癌中同时发生EGFR突变和ALK重组

Haoyue Hu1, Songtao Tan2,3, Meng Xie4

  • 1Department of Radiation Oncology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China.

Frontiers in pharmacology
|September 14, 2023
PubMed
概括

在非小细胞肺癌中,同时发生的表皮生长因子受体 (EGFR) 突变和形淋巴瘤激酶 (ALK) 重组是罕见的. 本案例研究突出了一个患有EGFR/ALK共同突变的患者,在EGFR-TKI治疗失败后,该患者对ALK-TKI治疗有反应.